The author sees Cannara's Q1 FY2026 results as solid, citing revenue growth, healthy margins, and a stronger balance sheet, while flagging high share-based compensation as a concern.
LOVE.V — LONG The author judges Cannara Biotech's Q1 FY2026 report as another solid result and says the company is moving in the right direction. The bullish view rests on increasing revenues, good margins, and a balance sheet where cash and receivables now cover current liabilities. The main stated concern is high share-based compensation, which the author attributes to Q4 bonuses and will monitor. No specific catalyst or time horizon is stated.
Overall, another very solid report for a company moving in the right direction
This Reddit post, published January 26, 2026, features u/Forest_City_Frolfer discussing LOVE.V. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Forest_City_Frolfer · Tickers: LOVE.V